AACR 2024 | INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma

Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, summarizes the emerging immunotherapeutic treatment landscape for patients with melanoma. The ongoing Phase III INTerpath-001 trial (NCT05933577) employs a combinatory therapeutic approach, using individualized neoantigen therapies (INTs) and pembrolizumab. Rather than using pembrolizumab alone, this immunotherapeutic combination has been evidenced in prior trial data as highly effective, lowering the hazard ratio for distant metastasis free survival. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.